Lung Peptide PTHrP1-34 Drives Pulmonary Fibrosis and May Be a New Treatment Target
PTHrP1-34 peptide from bronchial epithelial cells drives fibroblast activation and lung fibrosis in IPF, and targeting the PTHrP/PTH1R axis with antibodies, peptides, or gene silencing attenuated disease in mice.
Quick Facts
What This Study Found
PTHrP1-34 was elevated in IPF lung tissue and bronchoalveolar lavage, activated fibroblasts and ECM production, and targeting the PTHrP1-34/PTH1R axis with antibodies, peptides, or gene silencing attenuated pulmonary fibrosis in mice.
Key Numbers
How They Did This
Bulk and single-cell RNA-seq reanalysis of human IPF tissue, immunohistochemistry in IPF patients and bleomycin-treated mice, cell-based fibroblast activation assays, and preclinical evaluation of three therapeutic strategies in bleomycin mouse model.
Why This Research Matters
IPF affects 3 million people worldwide with a median survival of 3-5 years. A new druggable peptide target could lead to the first disease-modifying therapy.
The Bigger Picture
Identifying a specific paracrine peptide driving fibrosis opens a new therapeutic avenue that could complement existing antifibrotic drugs for IPF.
What This Study Doesn't Tell Us
Bleomycin mouse model doesn't fully replicate human IPF. Therapeutic strategies tested short-term. Human clinical translation needs validation.
Questions This Raises
- ?Could PTHrP1-34 blocking be combined with existing IPF drugs (nintedanib, pirfenidone)?
- ?Is PTHrP1-34 elevated in other fibrotic diseases beyond the lung?
- ?What is the optimal therapeutic modality for targeting the PTHrP/PTH1R axis clinically?
Trust & Context
- Key Stat:
- 3 blocking strategies worked Antibodies, peptides, and gene silencing targeting PTHrP1-34/PTH1R all reduced pulmonary fibrosis in mice
- Evidence Grade:
- Multi-modal study with human tissue validation, cell biology, and three preclinical therapeutic approaches. Strong evidence for a novel target.
- Study Age:
- Published in 2025.
- Original Title:
- Parathyroid hormone-related protein is a therapeutic target in idiopathic pulmonary fibrosis.
- Published In:
- Signal transduction and targeted therapy, 11(1) (2026)
- Authors:
- Fang, Xue-Quan, Lim, Suha, Lee, Yoon-Mi, Lim, Chang-Hoon, Kim, Han-Byeol, Joo, Jeong Ho, Han, Sang-Woo, Kim, Seohyun, Kim, Ji Hyung, Na, Kwon Joong, Park, Samina, Kim, Young Tae, Park, Jimyung, Park, Jooho, Lee, Jeong Seok, Shin, Eun-Young, Kim, Eung-Gook, Shin, Hyun-Woo, Lim, Ji-Hong
- Database ID:
- RPEP-15150
Evidence Hierarchy
Frequently Asked Questions
What is IPF and why is it hard to treat?
Idiopathic pulmonary fibrosis progressively scars the lungs, making breathing increasingly difficult. Current drugs slow but don't stop the disease. Finding what drives the scarring could lead to better treatments.
How does this peptide cause lung scarring?
PTHrP1-34 is released by airway lining cells and activates fibroblasts (scar-forming cells) through the PTH1R receptor. Blocking this peptide-receptor interaction reduced fibrosis in three different ways in mouse models.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15150APA
Fang, Xue-Quan; Lim, Suha; Lee, Yoon-Mi; Lim, Chang-Hoon; Kim, Han-Byeol; Joo, Jeong Ho; Han, Sang-Woo; Kim, Seohyun; Kim, Ji Hyung; Na, Kwon Joong; Park, Samina; Kim, Young Tae; Park, Jimyung; Park, Jooho; Lee, Jeong Seok; Shin, Eun-Young; Kim, Eung-Gook; Shin, Hyun-Woo; Lim, Ji-Hong. (2026). Parathyroid hormone-related protein is a therapeutic target in idiopathic pulmonary fibrosis.. Signal transduction and targeted therapy, 11(1). https://doi.org/10.1038/s41392-026-02578-8
MLA
Fang, Xue-Quan, et al. "Parathyroid hormone-related protein is a therapeutic target in idiopathic pulmonary fibrosis.." Signal transduction and targeted therapy, 2026. https://doi.org/10.1038/s41392-026-02578-8
RethinkPeptides
RethinkPeptides Research Database. "Parathyroid hormone-related protein is a therapeutic target ..." RPEP-15150. Retrieved from https://rethinkpeptides.com/research/fang-2026-parathyroid-hormonerelated-protein-is
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.